Skip to content
MedsAcross

Medicine

Sodium Phosphates 4020 mg/4140 mg per 15 mL injection

Sodium phosphate, dibasic, and Sodium phosphate, monobasic, · Intravenous · Amneal Pharmaceuticals
Available on requestPrescription onlyUS FDA

Sodium Phosphates 4020 mg/4140 mg per 15 mL injection is a prescription medicine containing Sodium phosphate, dibasic, and Sodium phosphate, monobasic, for intravenous use, marketed by Amneal Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F).

Key facts

Active ingredient (INN)
Sodium phosphate, dibasic, and Sodium phosphate, monobasic,
Brand
Sodium Phosphates
Strength
4020 mg/4140 mg per 15 mL
Dosage form
Injection
Route
Intravenous
Packs
25 vials of 15 mL
Marketing authorisation holder
Amneal Pharmaceuticals
Manufacturer
Amneal Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
20 October 2026
Identifiers
RxCUI 1872384DailyMed set ID 62db5220-13ec-4cb9-b705-8a908a174dbaNDC 80830-2310Application ANDA218274

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
25 vial in 1 carton / 15 mL in 1 vial80830-2310-5Amneal Pharmaceuticals20 October 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 10 May 1983Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Sodium phosphate, dibasic, and Sodium phosphate, monobasic, 4020 mg/4140 mg per 15 mL injection.

Compare 1

Other strengths and forms of Sodium phosphate, dibasic, and Sodium phosphate, monobasic,

Clinical summary

Sodium phosphate, dibasic, and Sodium phosphate, monobasic, is a fixed-dose combination medicine indicated as a source of phosphorus, for addition to large volume intravenous fluids, among other approved uses. MedsAcross supplies Sodium phosphate, dibasic, and Sodium phosphate, monobasic, for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Sodium phosphate, dibasic, and Sodium phosphate, monobasic,

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Sodium Phosphates 4020 mg/4140 mg per 15 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.